ValveDigest
Structural Heart Intelligence
This started because keeping up with the valve space meant checking twenty different websites every morning.
A trial result here. An FDA recall there. A JACC paper that changes how you think about durability. A company acquisition that shifts the competitive landscape. All happening at the same time, on different sites, with no thread connecting them.
ValveDigest is for anyone who works with valves — interventionalists, surgeons, fellows, researchers, industry, investors, regulators. The common thread is that you need to know what is happening in this space, understand why it matters, and not spend your morning hunting for it.
We pull from journals, trial registries, the FDA, company newsrooms, and conference feeds. We filter out everything that isn't relevant to structural heart. We surface the connections between things that look separate but aren't. A durability paper, a trial completion, and a stock move on the same day often tell one story (mostly!).
It just saves time.
Everything in one place.
What We Cover
Clinical News
TAVR, SAVR, mitral, tricuspid, structural heart updates from leading sources
Research
Peer-reviewed publications from NEJM, JACC, Circulation, EuroIntervention and more
Clinical Trials
Active and recruiting trials, enrollment updates, primary endpoint results
FDA & Regulatory
Device recalls, PMA approvals, MAUDE adverse events, safety signals
Industry
Company news, device launches, earnings, acquisitions, market intelligence
Research Funding
Active NIH grants and open funding opportunities in structural heart
Conferences
ACC, AHA, ESC, TCT, AATS, PCR London Valves and more
Market Data
15-minute delayed quotes for major structural heart and medtech companies
How It Works
Aggregate
We pull from RSS feeds, PubMed, FDA databases, ClinicalTrials.gov, NIH Reporter, and company newsrooms — continuously, automatically.
Filter
Every article, paper, and event is filtered against a curated list of structural heart keywords. Non-relevant content never enters the pipeline.
Synthesize
AI-assisted editorial synthesis generates two-sentence clinical summaries and a "Clinical Take" — the one sentence that tells you why it matters to your practice.
Rank
Content is scored by relevance and source authority. FDA decisions and NEJM papers rank higher than company press releases. Signal rises, noise falls.
Important Notice
ValveDigest is an information aggregation service. Content is for informational purposes only and does not constitute medical advice, clinical recommendations, or investment guidance. Always consult qualified healthcare professionals for clinical decisions. Market data is delayed approximately 15 minutes.
Contact
Questions, feedback, content removal requests, or sponsorship inquiries:
valvedigest@gmail.com